ArticleMultiple sclerosis journal - experimental, translational and clinical

Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy.

Stanley L Cohan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.